Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium; IPO price falls to lower range at $14.

智通财经2026/10/09 07:07

Show original

According to Zhitong Finance APP, TRex Bio Inc., an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised 116.7 million dollars through its IPO, pricing at the lower end of its indicated range.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zhitong Caijing APP has learned that early-stage biotechnology company TRex Bio Inc., which focuses on autoimmune and inflammatory diseases, raised 116.7 million US dollars through its IPO, pricing shares at the lower end of its offering range.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium; IPO price falls to lower range at $14.

You may also like

Crypto prices